iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations iRegene Therapeutics has received dual FDA recognitions for NouvNeu001—highlighting its potential to transform Parkinson's treatment with innovative cell therapy.

iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations #NouvNeu001 #FDA_Designation #iRegene_Therapeutics